AU2021259682A1 - Method of treatment using anti-CCL24 antibody - Google Patents

Method of treatment using anti-CCL24 antibody Download PDF

Info

Publication number
AU2021259682A1
AU2021259682A1 AU2021259682A AU2021259682A AU2021259682A1 AU 2021259682 A1 AU2021259682 A1 AU 2021259682A1 AU 2021259682 A AU2021259682 A AU 2021259682A AU 2021259682 A AU2021259682 A AU 2021259682A AU 2021259682 A1 AU2021259682 A1 AU 2021259682A1
Authority
AU
Australia
Prior art keywords
ccl24
monoclonal antibody
antibody
administration
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021259682A
Other languages
English (en)
Inventor
Arnon AHARON
Neta Barashi
Sharon Hashmueli
Adi Mor
Michal SEGAL SALTO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemomab Ltd
Original Assignee
Chemomab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemomab Ltd filed Critical Chemomab Ltd
Publication of AU2021259682A1 publication Critical patent/AU2021259682A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2021259682A 2020-04-22 2021-04-20 Method of treatment using anti-CCL24 antibody Pending AU2021259682A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013793P 2020-04-22 2020-04-22
US63/013,793 2020-04-22
PCT/IL2021/050447 WO2021214759A1 (en) 2020-04-22 2021-04-20 Method of treatment using anti-ccl24 antibody

Publications (1)

Publication Number Publication Date
AU2021259682A1 true AU2021259682A1 (en) 2022-10-20

Family

ID=75787181

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021259682A Pending AU2021259682A1 (en) 2020-04-22 2021-04-20 Method of treatment using anti-CCL24 antibody

Country Status (9)

Country Link
US (1) US20230235037A1 (enExample)
EP (1) EP4139352A1 (enExample)
JP (1) JP2023522907A (enExample)
KR (1) KR20230013037A (enExample)
CN (1) CN115427445A (enExample)
AU (1) AU2021259682A1 (enExample)
CA (1) CA3172627A1 (enExample)
IL (1) IL296579A (enExample)
WO (1) WO2021214759A1 (enExample)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) * 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
EP1706424B1 (en) * 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
US9067989B2 (en) 2009-01-28 2015-06-30 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
EP2490026A4 (en) * 2009-10-16 2013-08-21 Mochida Pharm Co Ltd MARKER ASSOCIATED WITH NON ALCOHOLIC STÉATOHÉPATITE
BR112012022223B1 (pt) * 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
DK3114139T3 (da) 2014-03-04 2022-09-12 Chemomab Ltd Anti eotaxin-2 antistoffer, der genkender supplerende ccr3-bindende chemokiner
CR20170060A (es) * 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
WO2016040882A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
US20180008707A1 (en) * 2015-02-13 2018-01-11 Sanofi Stable liquid formulation for monoclonal antibodies
JP7155009B2 (ja) * 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
EP4652926A3 (en) * 2016-10-12 2026-03-18 Bioverativ USA Inc. Anti-c1s antibodies and methods of use thereof
IL251024A0 (en) 2017-03-08 2017-06-29 Chemomab Ltd Antibodies against eutaxin 2 for use in the treatment of liver diseases
CN107198773A (zh) * 2017-06-08 2017-09-26 上海药明生物技术有限公司 重组抗pd‑l1全人单克隆抗体的液体制剂
EP3660155A4 (en) * 2017-07-27 2021-04-07 Daiichi Sankyo Company, Limited ANTI-CD147 ANTIBODY
CN109745559A (zh) * 2017-11-01 2019-05-14 三生国健药业（上海）股份有限公司 抗人il-17a的单克隆抗体的液体制剂
CN110354073B (zh) * 2018-04-09 2021-10-01 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的液体制剂

Also Published As

Publication number Publication date
JP2023522907A (ja) 2023-06-01
EP4139352A1 (en) 2023-03-01
IL296579A (en) 2022-11-01
WO2021214759A1 (en) 2021-10-28
KR20230013037A (ko) 2023-01-26
CA3172627A1 (en) 2021-10-28
US20230235037A1 (en) 2023-07-27
CN115427445A (zh) 2022-12-02

Similar Documents

Publication Publication Date Title
US20200040073A1 (en) Methods for administering anti-il-5 antibodies
ES2926700T3 (es) Anticuerpos anti Eotaxina-2 que reconocen quimiocinas de unión a CCR3 adicionales
WO2016086147A1 (en) Vedolizumab for the treatment of fistulizing crohn's disease
US20220119514A1 (en) Methods for altering body composition by administering a gdf8 inhibitor and an activin a inhibitor
EA031489B1 (ru) Способ лечения ревматоидного артрита
JP7375252B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
JP2016540761A (ja) 変形性関節症を治療するための組成物及び方法
CN114650846A (zh) 用基于铂的试剂和抗组织因子抗体-药物偶联物的组合治疗癌症的方法
KR101581517B1 (ko) Tgf-알파 및 에피레굴린에 결합하는 항체
EP3688031A1 (en) Treatment of atopic dermatitis
EP4139352A1 (en) Method of treatment using anti-ccl24 antibody
RU2832323C1 (ru) Способ лечения с использованием антитела против CCL24
TW202120546A (zh) 使用介白素-17（il-17）拮抗劑治療狼瘡性腎炎之方法
IL294941A (en) Inhibitors and their uses
WO2025078534A1 (en) Cd248 inhibitors and uses thereof
IL291807A (en) Dosing regimens for treating or preventing c5-associated diseases
KR20220064998A (ko) 콜레스테롤 관련 질환을 예방하거나 치료하기 위한 방법에 있어서 항 pcsk9 항체의 용도
EP4558219A1 (en) Neutralization of acyl-coa binding protein for the treatment of cardiac dysfunction
WO2025096435A1 (en) Treatment of complement-associated renal diseases
WO2025253161A1 (en) Methods for treating liver diseases using recombinant fusion proteins comprising interleukin-18-binding protein and antigen binding fragment to serum albumin
WO2024248867A1 (en) Methods of treating tgf beta-related disorders with anti-transforming growth factor beta 3 antibodies
AU2024292030A1 (en) Targeted treatment of complement-mediated disease through local complement inhibition based on urinary uc5b-9 detection
KR20250020474A (ko) IgG4-관련 질환을 치료하기 위한 방법 및 조성물
WO2025006989A2 (en) Methods for detection and treatment of cancer
CN118786147A (zh) 每月一次施用fviii模拟双特异性抗体的方法